Back to Browse Journals » International Journal of Nanomedicine » Volume 3 » Issue 1

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Authors Malgorzata Smola, Thierry Vandamme, Adam Sokolowski

Published 7 March 2008 Volume 2008:3(1) Pages 1—19

DOI http://dx.doi.org/10.2147/IJN.S1045

Malgorzata Smola1,2, Thierry Vandamme1, Adam Sokolowski2

1Université Louis Pasteur, Faculté de Pharmacie, Département de Chimie Bioorganique, Illkirch Graffenstaden, France; 2Wroclaw University of Technology, Faculty of Chemical Engineering, Wroclaw, Poland

Abstract: The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofluorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientific and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.

Keywords: nanotechnology, nanocarriers, nanoparticle, liposome, lung, pulmonary drug delivery, drug targeting, respiratory disease, microemulsion, bioavailability, micelle

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Enhanced brain delivery of lamotrigine with Pluronic® P123-based nanocarrier

Liu JS, Wang JH, Zhou J, Tang XH, Xu L, Shen T, Wu XY, Hong Z

International Journal of Nanomedicine 2014, 9:3923-3935

Published Date: 16 August 2014

Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation

Castagna A, Rinaldi S, Fontani V, Mannu P, Lotti Margotti M

Clinical Interventions in Aging 2011, 6:201-206

Published Date: 25 July 2011

Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine

Duncan RS, Xin H, Goad DL, Chapman KD, Koulen P

Clinical Ophthalmology 2011, 5:543-548

Published Date: 26 April 2011

Prevention of atherosclerosis in patients living with HIV

Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao

Vascular Health and Risk Management 2009, 5:287-300

Published Date: 26 March 2009

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Postoperative delirium in the elderly: diagnosis and management

Thomas N Robinson, Ben Eiseman

Clinical Interventions in Aging 2008, 3:351-355

Published Date: 6 June 2008